This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Lopinavir–ritonavir | |
|---|---|
| Drug name | Lopinavir–ritonavir |
| Tradename | Kaletra |
| Routes of administration | Oral |
| Class | Antiretroviral combination |
Lopinavir–ritonavir is a fixed-dose combination antiretroviral medication used primarily in the treatment of HIV/AIDS. It combines the protease inhibitor Lopinavir with the pharmacokinetic enhancer Ritonavir, and is distributed under brand names such as Kaletra by AbbVie. The combination has played roles in global public health responses coordinated by organizations like the World Health Organization and the United States Food and Drug Administration.
Lopinavir–ritonavir is indicated for treatment of HIV/AIDS in adults and pediatric populations, often in combination with nucleoside reverse transcriptase inhibitors such as Zidovudine and Lamivudine. Clinical guidelines from bodies like the European Medicines Agency and the National Institutes of Health recommend its use in specific salvage or alternative regimens, particularly where resistance patterns compromise first-line options like regimens based on Dolutegravir or Efavirenz. During the COVID-19 pandemic, lopinavir–ritonavir was evaluated in randomized trials including multinational consortia such as RECOVERY Trial and the World Health Organization Solidarity trial, though major trials did not demonstrate clear benefit for SARS-CoV-2 infection.
Lopinavir acts as an inhibitor of the HIV-1 protease enzyme, preventing proteolytic cleavage of the Gag-Pol polyprotein and thereby yielding immature, noninfectious viral particles; ritonavir inhibits cytochrome P450 3A4 (CYP3A4) to boost lopinavir plasma concentrations. Pharmacokinetic parameters were characterized in studies involving institutions like the United Kingdom Medicines and Healthcare products Regulatory Agency and the Food and Drug Administration, showing lopinavir exposure increased several-fold with ritonavir coadministration. The combination exhibits high plasma protein binding and is metabolized primarily via CYP3A4, with enterohepatic recirculation implicated in elimination patterns described in pharmacology texts and trials conducted by academic centers such as Johns Hopkins University and Imperial College London.
Common adverse effects reported in clinical trials and postmarketing surveillance include gastrointestinal symptoms documented by hospitals like Mayo Clinic and Cleveland Clinic, metabolic disturbances observed in cohorts tracked by Harvard Medical School clinicians, and hepatotoxicity flagged by regulators including the European Medicines Agency. Patients may experience diarrhea, nausea, elevated serum transaminases, hypertriglyceridemia, and insulin resistance, with rare reports of severe cutaneous adverse reactions noted in case series published from tertiary centers such as Massachusetts General Hospital and Mount Sinai Health System.
Because ritonavir is a potent inhibitor of CYP3A4, lopinavir–ritonavir interacts with many agents including statins like Simvastatin and Lovastatin, antiarrhythmics such as Amiodarone, and immunosuppressants like Tacrolimus and Cyclosporine. Co-administration with drugs metabolized by CYP3A4 has prompted warnings from regulatory authorities including the United States Food and Drug Administration and the European Medicines Agency; management often requires consultation with specialist services at institutions like University College London Hospitals or use of therapeutic drug monitoring recommended by professional bodies such as the British HIV Association. Concomitant use with certain antimicrobials, antiepileptics, and herbal products like St. John's wort is contraindicated due to risk of loss of virologic control or toxicity, issues addressed in resources from organizations like the Centers for Disease Control and Prevention.
Standard adult dosing historically has been two tablets of the fixed-dose combination twice daily, each tablet containing 200 mg lopinavir with 50 mg ritonavir, with adjustments for concomitant drugs recommended by authorities such as the World Health Organization and the United States Department of Health and Human Services. Pediatric dosing is weight-based and formulations include oral solution and tablets, with guidance from pediatric HIV programs at institutions like Baylor College of Medicine and Great Ormond Street Hospital. Administration considerations include taking with food to enhance absorption, monitoring of lipid profiles and liver function as advised by clinical practice guidelines from bodies such as the European AIDS Clinical Society.
Development of lopinavir–ritonavir involved collaborative research between pharmaceutical companies and academic centers, culminating in approval by regulators including the United States Food and Drug Administration in the early 2000s and subsequent global distribution by AbbVie and predecessor companies. The strategy of ritonavir boosting emerged from pharmacokinetic research at universities such as University of Liverpool and University of California, San Francisco, building on protease inhibitor research that traced back to early antiretroviral discoveries at institutions like National Institutes of Health (United States). The combination featured in global scale-up initiatives supported by programs including the President's Emergency Plan for AIDS Relief and the Clinton Health Access Initiative, influencing treatment access in regions like sub-Saharan Africa and South Asia.
Lopinavir–ritonavir has been central to debates on drug pricing, access to medicines, and intellectual property policies discussed in forums like the World Trade Organization and by advocacy groups such as Médecins Sans Frontières. Patent disputes and licensing agreements involved entities including AbbVie and generic manufacturers in countries like India and Brazil, affecting procurement by global health purchasers such as the Global Fund to Fight AIDS, Tuberculosis and Malaria. Media attention during the COVID-19 pandemic brought the drug into public discourse alongside other therapeutics evaluated by bodies such as the National Institutes of Health (United States), influencing perceptions of repurposing antiretrovirals in emerging infectious disease outbreaks.
Category:Antiretroviral drugs